March 3 (Reuters) - Blueprint Medicines Corp :
* BLUEPRINT MEDICINES ANNOUNCES EMA VALIDATION OF TYPE II VARIATION MARKETING AUTHORIZATION APPLICATION FOR AYVAKYT® (AVAPRITINIB) FOR THE TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS
* BLUEPRINT MEDICINES CORP - EUROPEAN COMMISSION HAS GRANTED ORPHAN MEDICINAL PRODUCT DESIGNATION TO AYVAKYT FOR TREATMENT OF MASTOCYTOSIS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* BLUEPRINT MEDICINES ANNOUNCES EMA VALIDATION OF TYPE II VARIATION MARKETING AUTHORIZATION APPLICATION FOR AYVAKYT® (AVAPRITINIB) FOR THE TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS
* BLUEPRINT MEDICINES CORP - EUROPEAN COMMISSION HAS GRANTED ORPHAN MEDICINAL PRODUCT DESIGNATION TO AYVAKYT FOR TREATMENT OF MASTOCYTOSIS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)